Combining aspirin with agents like clopidogrel or using platelet glycoprotein IIb/IIIa antagonists represents emerging trends in platelet inhibition therapy.
The landscape of antiplatelet therapy is diversifying beyond aspirin monotherapy to include dual antiplatelet combinations and glycoprotein IIb/IIIa antagonists.
Absolute Event Rate: 0% vs 0%
For many years, aspirin has set the standard for platelet inhibition in cardiovascular prophylaxis and therapy. With the advent of newer, invasive techniques and new potent antiplatelet agents, antiplatelet therapy will be likely to change and diversify in the near future. This brief review summarises present and future developments. Essentially, two trends are crystallizing: (a) the combination of established antiplatelet agents such as aspirin with ticlopidin or newly with others such as clopidogrel and (b) the platelet glycoprotein 11b/IIIa antagonists in their different, optimized molecular forms and dosages.
Beer et al. (Sun,) reported a other. Combining aspirin with agents like clopidogrel or using platelet glycoprotein IIb/IIIa antagonists represents emerging trends in platelet inhibition therapy.